Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases

Mitsuhashi, Atsushi; Okuma, Yusuke; Zenke, Yoshitaka; Hosomi, Yukio

doi:10.3892/mco.2018.1710

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone metastasis is common in patients with advanced lung cancer, with the reported incidence of bone metastasis in non-small cell lung cancer ranging from 30%-55% [23,24]. In extensive small cell lung cancer, about 40% of patients have bone metastasis [25]. In the present study, patients with ADC and SCLC often had multiple systemic metastases, and FAPI-04 uptake in bone metastases was higher than that in other tissues and organs.…”

Section: Discussionsupporting

confidence: 39%

18F-NOTA-FAPI-04 uptake in metastatic lesions on PET/CT imaging can distinguish different pathological types of lung cancer

Ye¹,

Chen²,

Fu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose Radionuclide-labeled fibroblast-activation-protein inhibitor 04 (FAPI-04) as a positron emission tomography (PET) imaging tracer can reveal the localized expression of fibroblast activation protein (FAP), a cell-surface serine protease that is highly upregulated in more than 90% of epithelial carcinomas. In this study, we quantified the 18F-NOTA-FAPI-04 uptake on PET/computed tomography (CT) imaging in different pathological types of lung cancer and metastatic tumors. Methods We prospectively enrolled 61 patients with histopathologically proven primary lung cancer with metastases.PET/CT scanning was performed before any antitumor therapy and 1hour after injection of 235.10 ± 3.89 MBq of 18F-NOTA-FAPI-04. Maximum standard uptake values (SUVmax) were calculated for comparison among primary and metastatic lesions. Results Sixty-one patients with adenocarcinoma (ADC, n = 30), squamous cell carcinoma (SCC, n = 17), and small cell lung cancer (SCLC, n = 14) were enrolled in this study, and 61 primary tumors and 199 metastases were evaluated. No difference in18F-NOTA-FAPI-04 uptake was observed among primary ADC, SCC, and SCLC tumors (P = 0.198).Additionally, no difference in uptake was found between primary and metastatic lesions of lung cancer with the same pathological type (P > 0.05).However, uptake did differ among metastases of differing pathological type (P < 0.001). The SUVmax of metastatic lymph nodes was highest for SCC, followed by ADC and then SCLC (P < 0.001).The SUVmax of bone metastases also was highest for SCC, followed by ADC and SCLC (P < 0.05), but no difference was observed between ADC and SCLC. The SUVmax of metastases in other organs was higher in SCC cases than in ADC cases, but did not differ between SCC and SCLC or ADC and SCLC. Bone metastases exhibited higher uptake than those of lymph nodes and other organs in SCC and ADC (P < 0.05), but not in SCLC. Conclusion 18F-NOTA-FAPI-04 PET/CT imaging revealed differences in FAP expression in metastases of lung cancer, with the highest expression specifically in bone metastases, and thus, may be valuable for distinguishing different pathological types of lung cancer.

show abstract

Section: Discussionsupporting

confidence: 39%

18F-NOTA-FAPI-04 uptake in metastatic lesions on PET/CT imaging can distinguish different pathological types of lung cancer

Ye¹,

Chen²,

Fu³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Bone metastasis is common in patients with advanced lung cancer, with the reported incidence of bone metastasis in non-small cell lung cancer ranging from 30 to 55% [ 25 , 26 ]. In extensive small cell lung cancer, about 40% of patients have bone metastasis [ 27 ]. In the present study, patients with ADC and SCLC often had multiple systemic metastases, and FAPI-04 uptake in bone metastases was higher than that in other tissues and organs.…”

Section: Discussionmentioning

confidence: 99%

[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer

Chen

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Heterogeneity is found in the tumor microenvironment among different pathological types of tumors. Radionuclide-labeled fibroblast-activation-protein inhibitor (FAPI), as an important tracer for non-invasive imaging of the tumor microenvironment, can be used to evaluate the expression of FAP in cancer-associated fibroblasts, macrophages, and tumor cells. Our aim was to explore the ability of [18F]AlF-NOTA-FAPI-04 positron emission tomography (PET)/computed tomography (CT) to distinguish different types of lung cancer by evaluating the uptake of this tracer in primary and metastatic lesions. Methods We prospectively enrolled 61 patients with histopathologically proven primary lung cancer with metastases. PET/CT scanning was performed before any antitumor therapy and 1 h after injection of 235.10 ± 3.89 MBq of [18F]AlF-NOTA-FAPI-04. Maximum standard uptake values (SUVmax) were calculated for comparison among primary and metastatic lesions. Immunohistochemical staining for FAP was performed on tumor specimens. Results Sixty-one patients with adenocarcinoma (ADC, n = 30), squamous cell carcinoma (SCC, n = 17), and small cell lung cancer (SCLC, n = 14) were enrolled in this study, and 61 primary tumors and 199 metastases were evaluated. No difference in [18F]AlF-NOTA-FAPI-04 uptake was observed among primary ADC, SCC, and SCLC tumors (P = 0.198). Additionally, no difference in uptake was found between primary and metastatic lesions of lung cancer with the same pathological type (P > 0.05). However, uptake did differ among metastases of differing pathological types (P < 0.001). The SUVmax of metastatic lymph nodes was highest for SCC, followed by ADC and then SCLC (P < 0.001). The SUVmax of bone metastases also was highest for SCC, followed by ADC and SCLC (P < 0.05), but no difference was observed between ADC and SCLC. The SUVmax of metastases in other organs was higher in SCC cases than in ADC cases but did not differ between SCC and SCLC or ADC and SCLC. Bone metastases exhibited higher uptake than those of lymph nodes and other organs in SCC and ADC (P < 0.05) but not in SCLC. Positive correlations were found between FAPI uptake and FAP expression in surgical plus biopsy specimens (r = 0.439, P = 0.012) and surgical specimens (r = 0.938, P = 0.005). Conclusion [18F]AlF-NOTA-FAPI-04 PET/CT imaging revealed differences in FAP expression in metastases of lung cancer, with the highest expression specifically in bone metastases, and thus, may be valuable for distinguishing different pathological types of lung cancer.

show abstract

“…In addition, with the development of technology, FDG-PET imaging and CT fusion has become a new model for a variety of oncology imaging (PET/CT) (37,38). The advantage of PET/CT over traditional MRI is that it can detect changes in metabolism before structural changes occur in the lesion tissues, whereas, MRI can only detect changes in the structure of the disease after structural changes in the tissue (39).…”

Section: Modeling Timementioning

confidence: 99%

Comparison of diagnostic efficacy of MRI and PET/CT in lung cancer of mouse with spinal metastasis

Liu

Xiao

et al. 2020

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study aimed to compare the diagnostic efficacy of MRI and PET/CT in lung cancer of mouse with spinal metastasis. 40 healthy Balb/c nude mice were selected. 0.1 ml of human lung cancer cell A549 bacterial suspension was injected by the left ventricle injection method to establish a lung cancer spinal metastasis model, and the abnormal signs of the nude mice were closely observed. When the body weight was reduced by 20%, micro PET/CT imaging and small coil MRI imaging were applied after intraperitoneal injection of thiopental anesthesia in nude mice. After the imaging was completed, the nude mouse was dissected and the spinal tumor was removed. The nature of spinal metastases was diagnosed by the pathology department. 5 nude mice died of abdominal infection, 2 nude mice had no spinal tumors, and the remaining 33 nude mice were successfully modeled. 33 nude mice were confirmed by pathology to have 64 metastatic vertebral lesions, among them, there were 7 cervical vertebrae, 24 thoracic vertebrae, 16 lumbar vertebrae, 6 sacral vertebrae and 11 caudal vertebrae. The sensitivity of MRI in the diagnosis of spinal metastases was 78.13%, and specificity was 56.25%. The sensitivity of PET/CT for the diagnosis of spinal metastases was 92.19%, and specificity was 78.95%. The specificity and positive predictive value of PET/CT for the diagnosis of spinal metastases were not significantly different from those of MRI (P> 0.05). The sensitivity, accuracy and negative predictive values were significantly higher than those of MRI (P< 0.05). PET/CT is superior to MRI in the diagnosis of spinal metastases, and its sensitivity, accuracy and negative predictive values were significantly higher than those of MRI (P< 0.05). It is worthy to be further promoted in clinical practice.

show abstract

Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases

Cited by 3 publications

References 22 publications

18F-NOTA-FAPI-04 uptake in metastatic lesions on PET/CT imaging can distinguish different pathological types of lung cancer

18F-NOTA-FAPI-04 uptake in metastatic lesions on PET/CT imaging can distinguish different pathological types of lung cancer

[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer

Comparison of diagnostic efficacy of MRI and PET/CT in lung cancer of mouse with spinal metastasis

Contact Info

Product

Resources

About